MOLECULAR THERAPEUTICS RESEARCH PROGRAM

分子治疗计划(MT)的目标是促进思想的交流、合作和 合作导致翻译的基础研究集中在小说的识别和发展上 将治疗学转化为临床应用，并利用基础研究回答临床相关问题 提高癌症的治疗水平。机器翻译计划提供了一个讨论和推进 靶标识别、药物发现、药物作用机制和翻译方面的新进展 这些方法进入了新的相关和治疗性临床试验。该计划目前有27个 来自7个部门的成员和总计820万美元的资金，其中近400万美元(61%)来自 美国国家情报局。在过去的5年中，效率超过240篇，其中16%是程序内的，26%是程序间的 协作性出版物。18名计划教员参与了计划内，18名参与了计划间 合作，为高度互动的研究计划提供了强有力的证据。近期 程序性的亮点包括脂肪酸合酶途径作为一种独立的 乳腺癌进展的标志物，以及认识到它可以靶向抑制肿瘤生长。 其他正在研究的分子靶标包括Hedgehog信号通路中的蛋白质，这是 在非小细胞肺癌中经常被激活。新的药物，如新型蛋白酶体抑制剂和 抗凋亡蛋白Mcl-1和Bcl-2的抑制物正在研究中，预计 将这些药物带到莫里斯棉花癌症中心进行临床试验。开发了新的治疗策略 已被转化为I期临床试验的MT计划包括顺铂加 Chk1抑制剂UCN-01。在这项研究中，连续的肿瘤活检被用来监测肿瘤的生物活性。 组织。其他研究人员开发了新的技术和补充方法来确定 预测标记物和治疗策略，MT计划的一个重要目标是测试这些 在NCCC的相关和治疗临床试验的想法。同样值得特别注意的是一系列 在新辅助治疗环境中使用化疗放射治疗胰腺癌的I期和II期临床试验 确定了这种高度侵袭性疾病的一种有希望的治疗方法，并展示了该计划的 对癌症患者疾病结局的影响。

The goal of the Molecular Therapeutics Program (MT) is to foster the exchange of ideas, cooperation, and collaboration leading to translation of basic research focused on the identification and development of novel therapeutics into clinical applications, and to use basic research to answer clinical questions related to improving the treatment of cancer. The MT Program provides a forum for discussion and advancement of new developments in target identification, drug discovery, and mechanisms of drug action, and for translating these approaches into novel correlative and therapeutic clinical trials. The Program currently has 27 members from 7 departments and $8.2 millon in total funding, of which almost $4 million (61%) is from the NCI. The productivity over the past 5 years exceeds 240 papers, including 16% intra-program and 26% interprogram collaborative publications. Eighteen Program faculty participated in intra-program and 18 in interprogram collaborations, providing strong evidence of a highly interactive research program. Recent programmatic highlights include evidence for the role of the fatty acid synthase pathway as an independent marker of breast cancer progression, and the recognition that it can be targeted to suppress tumor growth. Other molecular targets under investigation include proteins in the Hedgehog signaling pathway, which is frequently activated in non-small cell lung cancer. New agents such as novel proteasome inhibitors and suppressors of the anti-apoptotic proteins Mcl-1 and Bcl-2 are under investigation, with the expectation of bringing these drugs to clinical trial at Morris Cotton Cancer Center. Novel treatment strategies developed in the MT Program that have been translated into Phase I clinical trials include the combination of cisplatin plus the Chk1 inhibitor UCN-01. In is study serial tumor biopsies were used to monitor biological activity in tumor tissue. Other investigators have developed novel technologies and complementary approaches to define predictive markers and therapeutic strategies, and an important goal of the MT Program is to test these ideas in correlative and therapeutic clinical trials at the NCCC. Also worthy of particular notice is a series of Phase I and II clinical trials in pancreatic cancer using chemoradiation in the neoadjuvant setting that has identified a promising treatment approach in this highly aggressive disease and demonstrates the Program's impact on disease outcome in cancer patients.